Although pharmas are cutting back on internal neuroscience R&D programs, the number of precompetitive consortia backed by industry continues to rise. Most initiatives are focused on developing better disease models and discovering new biomarkers. The challenge going forward will be to push the boundaries of the precompetitive space to advance the discovery of new disease-modifying targets and mechanisms.